<DOC>
	<DOCNO>NCT02220153</DOCNO>
	<brief_summary>This study design evaluate safety tolerability single ascending dos UCB7665 administer intravenous subcutaneous infusion healthy subject .</brief_summary>
	<brief_title>A First-In-Human Study With Single Dose UCB7665 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male female volunteer nonchildbearing potential give consent write informed consent form Healthy volunteer age 18 64 year old normal weight determine body mass index ( BMI ) 18 30 kg/m^2 , body weight least 50 kg male subject 45 kg female subject Subjects blood pressure ( BP ) pulse within normal range supine position 5 minute rest Subject clinical laboratory test result within reference range test laboratory test result outside specified range deem clinically nonsignificant Subject 's electrocardiogram ( ECG ) consider `` normal '' `` abnormal '' clinically nonsignificant Subject significant blood loss , donate blood excess 400 mL blood blood product within 90 day Day 2 , plan donate blood clinical study Subject total Immuneglobulin G &lt; 7 g/L &gt; 16 g/L Screening Visit Subject absolute neutrophil count &lt; 1.5x10^9/L and/or lymphocyte count &lt; 1.0x10^9/L Subject know viral hepatitis , positive test Hepatitis B surface antigen Hepatitis C virus antibody positive Subject test positive Human Immunodeficiency Virus ( HIV ) 1/2 antibody Subject past medical history family history primary immunodeficiency Subject splenectomized Subject positive TIGRA ( T cell interferon Î³ release assay ) Screening Visit . If TIGRA available , purified protein derivative ( PPD ) skin test substitute and/or chest xray perform within 6 month Screening Visit show evidence latent/active Tuberculosis ( TB ) Subject past ( last 12 month ) present substance abuse/dependence concurrent medical condition opinion investigator could confound clinical study interpretation affect subject 's ability fully participate clinical study Subject know hypersensitivity component Investigational Medicinal Product ( IMP ) Subject active infection serious infection ( result hospitalization require parenteral antibiotic treatment ) within 6 week first dose IMP Subject 12lead electrocardiogram ( ECG ) change consider clinically significant upon medical review Subject renal impairment Subject hepatic impairment Subject correct serum calcium &gt; 11.5 mg/dL ( &gt; 2.9 mmol/L ) &lt; 8.0 mg/dL ( &lt; 2.0 mmol/L ) Screening Visit Subject active neoplastic disease history neoplastic disease within 5 year entry clinical study Subject acute chronic illness , opinion investigator study physician , could pose threat harm subject Subject receive vaccination within 6 week Screening Visit intend vaccination Day 43 Safety Followup Period Subject receive IMP experimental procedure within 90 day first dose IMP Subject require treatment Paracetamol clinical study Subject vulnerable subject ( e.g . subject kept detention ) ( Declaration Helsinki , 1996 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Monoclonal antibody</keyword>
	<keyword>subject</keyword>
	<keyword>First human</keyword>
</DOC>